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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To establish the effectiveness of interventions delivered by mobile phone to improve adherence to medication prescribed for the primary
prevention of cardiovascular disease in adults.
B A C K G R O U N D
Description of the condition
Cardiovascular disease (CVD) is a major cause of disability and
mortality throughout the world, and contributes substantially to
the escalating costs of health care (WHO 2011). An estimated
17.7million people died fromCVDs in 2015, accounting for 31%
of all global deaths (WHO 2016). However, premature fatal and
non-fatal CVD is considered to be largely preventable through the
control of risk factors (WHO 2011).
Primary prevention of CVD refers to actions taken to reduce the
incidence of clinical events due to coronary heart disease (CHD),
cerebrovascular disease (CeVD) and peripheral vascular disease,
among people with risk factors who have not yet developed clini-
cally manifest CVD (WHO 2007). Primary prevention of CVD
consists of lifestyle modifications (e.g. smoking cessation, increas-
ing physical activity) and drug therapy (Piepoli 2016).
Lipid-lowering and anti-hypertensive drug therapies for primary
prevention are cost-effective in reducingCVDmorbidity andmor-
tality among high-risk people and are recommended by interna-
tional guidelines (Piepoli 2016; WHO 2007). Recommendations
relating to the use of antiplatelet drugs for primary prevention
vary. The European Society of Cardiology (ESC) states that as-
pirin cannot be recommended in primary prevention due to its
increased risk of major bleeding (Piepoli 2016); however, the U.S.
Preventive Services Task Force (USPSTF) recommends the use of
aspirin when the 10-year risk of CVD events reaches such a level
that the benefits of aspirin, in terms of CVD events prevented,
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outweigh the potential harm of increased gastrointestinal haem-
orrhage (USPSTF 2014).
Adherence to long-term medication is less than ideal and results
in costs in both health and economic terms (Piepoli 2016). Meta-
analyses have estimated rates of adherence to cardiovascular med-
ications ranging from 50% to 60% (Chowdhury 2013; Naderi
2012), and there is some evidence that adherence is lower for pri-
mary prevention (Naderi 2012).
One study of health records of over 430,000 people in UK general
practices found that 47% of people prescribed statins for primary
preventiondiscontinued treatment (indicated by a greater than90-
day gap between prescriptions), among whom, 72%who restarted
treatment (Vinogradova 2016). One study of Finnish healthcare
registers found that 53% of women prescribed statin therapy for
primary prevention were adherent (defined as exceeding 80% of
the prescribed regimen) (Lavikainen 2016). It has been estimated
that approximately 9% of cases of CVDs in the EU could be at-
tributed to poor adherence to vascular medications (Chowdhury
2013). Improving adherence to medications for the primary pre-
vention of CVD would help to maximise the clinical benefits for
the wider population (WHO 2003). Therefore, there is consider-
able scope for increasing adherence to prescribed medicine, and
so, reducing morbidity, mortality and healthcare costs.
Description of the intervention
Mobile phone ownership is almost universal in high-income coun-
tries and estimated to have reached over 90% in low- and middle-
income countries (ICT 2016). Given the broad reach of mobile
phones and the potential for automation of delivery, interventions
delivered by mobile phone are a potentially cost-effective strategy
to improve medication adherence. A range of media can be deliv-
ered through mobile phones including text messages, picture mes-
sages, interactive-voice response, telephone calls and, with increas-
ing ownership of smart phones with Internet capabilities (ICT
2016), mobile applications.
How the intervention might work
The World Health Organization (WHO) has identified a wide
range of factors associatedwithmedication non-adherence (WHO
2003). Mobile phone-based interventions have the potential to
target a number of these factors. For example, lack of adherence
resulting from poor provider-patient communication and com-
plex/confusing advice or poor recall of information provided in
consultations may be addressed through text messages providing
short and simply worded snippets of information. Experiences of
adverse effects can be targeted throughmobile phone-delivered in-
terventions by providing information about medication and facil-
itating a link to a healthcare professional for people experiencing
problems with their medication. Lack of social support has also
been linked to poormedication adherence and previous qualitative
research found that the receipt of text message-based intervention
provided social support (Douglas 2013). Mobile phone-delivered
interventions can be designed to target psychological factors such
as lack of motivation and low self-efficacy (Free 2016).
Existing interventions targeting adherence to CVD medication
have employed mobile technologies to: deliver medication re-
minders (Park 2014a); encourage self-monitoring of medication
intake (Park 2014a); encourage habit formation relating to med-
ication-taking behaviours (Bobrow 2014); provide information
(Bobrow 2014; Park 2014a); and facilitate links to healthcare ser-
vices where required (Bobrow 2014; Piette 2012).
Systematic reviews assessing the effect of mhealth interventions on
medication adherence for a range of conditions, including HIV,
non-communicable diseases, and prevention of transplant rejec-
tion have reported significant improvements (Anglada-Martinez
2015; Park 2014b) and a recent RCT foundmobile phonemessag-
ing to be effective in improving contraceptive use (Smith 2015).
Few adverse effects ofmobile phone-based interventions have been
reported; potential, but rare, adverse events may include road traf-
fic accidents (Caird 2014).
Why it is important to do this review
Systematic reviews evaluating the effect ofmobile health (mhealth)
interventions have reported promising results relating to improved
medication adherence (Anglada-Martinez 2015; Park 2014b).
One systematic review of interventions delivered by text-messag-
ing targeting medication prescribed for secondary prevention of
CVD is currently underway (Adler 2015). However, no systematic
review has specifically examined the effect of mobile phone-based
interventions on adherence tomedications for the primary preven-
tion of CVD. Mobile phone-based interventions are of particular
interest given their low-cost and potential for widespread delivery.
O B J E C T I V E S
To establish the effectiveness of interventions delivered by mobile
phone to improve adherence to medication prescribed for the pri-
mary prevention of cardiovascular disease in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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We will include randomised controlled trials (RCTs) of parallel
group design that randomise by participant or by cluster. We will
not include cross-over trials as this design would be inappropriate
for assessing effects on cardiovascular events or mortality, due to
the irreversible of these events. We will only include trials with a
minimum of one-year follow-up in order that the outcome mea-
sures relate to longer-term, sustained medication adherence be-
haviours and outcomes. We will include studies published as full
text and as abstract only, and unpublished data.
Types of participants
We will include adults (aged 18 years and over) who have been
prescribedmedication for the primary prevention of CVD. As this
review will focus on the primary prevention of CVD, we will only
include studies involving participants who have not had a prior
CVD event, defined as: a previous myocardial infarction (MI),
stroke, revascularisation procedure (coronary artery bypass graft-
ing (CABG) or percutaneous coronary intervention (PCI)), peo-
ple with angina, and people with angiographically defined CHD.
Where we identify trials that include a subset of eligible partici-
pants, we will contact the authors to request data for only those
participants of interest. In the event that we are unable to access
these data, we will apply a cut-off whereby only trials in which at
least 75% of participants meet the criteria for primary prevention
will be included.
Types of interventions
We will include trials of interventions delivered wholly or partly
by mobile phone to improve adherence to cardiovascular medica-
tions prescribed for the primary prevention of CVD. We will in-
clude interventions targeting adherence to antihypertensive drugs
(thiazide-like diuretic, angiotensin-converting enzyme (ACE) in-
hibitor, calcium channel blocker, beta-blocker); lipid-lowering
drugs (statins); and antiplatelet drugs (low-dose aspirin, non-as-
pirin antiplatelet drugs). We will only include trials targeting ad-
herence to at least one of these medications. We will also include
trials of interventions that target medication adherence alongside
other lifestyle modifications.
Intervention: any mobile phone-specific delivery mechanism, in-
cluding short messaging service (SMS), multimedia messaging
(MMS), applications (apps) and InteractiveVoiceResponse (IVR).
We will include interventions employing a mix of delivery mech-
anisms of which at least one is mobile phone-based, for example,
interventions delivered bymobile phones in combinationwith tra-
ditional methods such as face-to-face communication and links to
other types of support (e.g. healthcare support worker, telephone
calls, web pages).
Comparator: usual care and active controls where the control
group intervention has no component delivered by a mobile
phone-specific delivery mechanism.
Types of outcome measures
Primary outcomes
• Objective measures of adherence to treatment (low-density
lipoprotein (LDL)-cholesterol for the effect of statins; blood
pressure for antihypertensive drugs; heart rate for the effect of
atenolol; urinary 11-dehydrothromboxane B2 for the antiplatelet
effects of aspirin).
• Combined CVD event (fatal or non-fatal events).
• Adverse effects including self-reported road traffic accidents.
Secondary outcomes
• Indirect measures of adherence to treatment (self-report,
pill counts, medication event monitoring systems (MEMS),
pharmacy prescription data).
• Fatal cardiovascular events.
• Non-fatal cardiovascular events (CHD, stroke).
• Health-related quality of life assessed using validated
instruments (e.g. 36-Item Short Form Health Survey (SF-36),
EQ-5D).
• Cognitive outcomes (any measures of: satisfaction with
medication, medication-taking self-efficacy, autonomy related to
medication, attitudes (e.g. concerns about medicine adverse
effects)).
• Costs.
We will also report on the following process measures: extent of
intervention received (e.g. number of text messages received, mea-
sures of use of allocated mobile application) and acceptability of
intervention.
Reporting one of more of the outcomes listed here in the trial will
not be an inclusion criterion for the review.
Where outcomes (primary or secondary) are measured at multiple
time points, wewill extract data for the final point ofmeasurement.
Search methods for identification of studies
Electronic searches
Wewill identify trials through systematic searches of the following
bibliographic databases from inception to the date of search:
• Cochrane Central Register of Controlled Trials
(CENTRAL) in the Cochrane Library;
• MEDLINE (Ovid);
• Embase (Ovid);
• CINAHL Plus (EBSCOhost);
• Conference Proceedings Citation Index-Science (CPCI-S)
on Web of Science (Thomson Reuters).
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The preliminary search strategy forMEDLINE (Ovid) (Appendix
1) will be adapted for use in the other databases. The Cochrane
sensitivity-precision maximising RCT filter (Lefebvre 2011) will
be applied toMEDLINE (Ovid) and adaptations of it to the other
databases, except CENTRAL.
We will carry out a search of
ClinicalTrials.gov (www.ClinicalTrials.gov) and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) Search Portal
(apps.who.int/trialsearch/) for ongoing or unpublished trials.
We will impose no restriction on language of publication.
We will not perform a separate search for adverse effects of mobile
phone-based interventions targeting medication adherence. We
will consider adverse effects described in included studies only.
Searching other resources
We will check the reference lists of all included studies and we
will review relevant articles for additional references. We will also
examine any relevant retraction statements and errata for included
studies.
Data collection and analysis
Selection of studies
Two review authors (MP and SB) will independently screen the
titles and abstracts of all identified potential studies to decide
whether to retrieve the full text (eligible or potentially eligible/un-
clear studies) or to discard the study. Two review authors (MP and
SB) will independently screen the retrieved full texts to identify
studies for inclusion and identify and record reasons for exclusion
of the ineligible studies in a ’Characteristics of excluded studies’
table. We will endeavour to resolve any disagreements though dis-
cussion, and if necessary, a third review author (CF or PP) will
arbitrate. We will exclude any duplicates. Multiple reports of the
same RCT study will be collated into a single entry. We will com-
plete a PRISMA flow diagram.
Data extraction and management
We will use a standardised, prepiloted form to extract data from
the included studies for assessment of study quality and evidence
synthesis. We will contact chief investigators for additional infor-
mation if necessary. We will extract the following information.
• Methods: study design; total duration of study; study
setting and date of study.
• Participants: number randomised; number lost to follow-
up/withdrawn; number analysed; mean age; age range; gender;
proportion meeting criteria of ’primary prevention’; and
inclusion criteria and exclusion criteria.
• Interventions: intervention; comparison; concomitant
medications; excluded medications; intervention delivery
mechanism (text messages/MMS/mobile application/combined);
how intervention was developed; behaviour change technique(s)
employed; if intervention was personalised; and frequency and
duration of intervention receipt.
• Outcomes: primary and secondary outcomes specified and
collected; adverse effects; and time points reported.
• Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (MP and SB) will independently extract data
and resolve any differences by returning to the original study re-
ports and discussion with a third review author (CF or PP) where
necessary. One review author (MP) will transfer data into the Re-
view Manager 5 (RevMan 2014). To ensure that there are no er-
rors in data entry, one review author (SB) will check that the data
entered into Review Manager 5 are consistent with those in the
data extraction form.
Assessment of risk of bias in included studies
Two review authors (MP and SB)will independently assess the risk
of bias for each study using the criteria detailed in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
For each of the following domains, we will grade the potential bias
as high, low or unclear.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other biases.
We will resolve any disagreements by discussion. Where necessary,
we will consult a third review author (CF or PP) to arbitrate. We
will construct a ’Risk of bias’ table including justifications for our
judgements. Where information relating to the risk of bias has
come fromunpublisheddata or correspondencewith an author, we
will note this.Wewill summarise the risk of bias judgements across
different studies for each of the domains listed. When considering
treatment effects, we will take into account the risk of bias for the
studies that contribute to that outcome.
Given the nature of the interventions to be included in this review,
it is likely that blinding of participants and personnel will be im-
possible, therefore, we expect trials to be categorised at high risk
of bias on this domain. For the overall study assessment, we will
categorise a trial as being at low risk of bias if it was rated as low
risk in all the domains listed above (with the exception of blinding
of participants and personnel). Trials that have been rated as high
or unclear risk of bias on any of the domains (except blinding of
participants and personnel) will be categorised as being at high
risk of bias.
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Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous outcome data as risk ratios with
95% confidence intervals. We will analyse continuous outcome
data as mean differences with 95% confidence intervals, or if a
continuous outcome has been measured in multiple ways, as a
standardised mean difference with 95% confidence intervals. We
will enter data presented as a scale with a consistent direction of
effect. We will report any skewed data identified as medians and
interquartile ranges.
Unit of analysis issues
We will include RCTs with parallel design. If we identify cluster
RCTs for inclusion, we will analyse the data accounting for clus-
tering using the intracluster coefficient (ICC).
If we identify multi-arm trials for inclusion, where there is more
than one relevant intervention arm but only one control arm, the
intervention arms will be pooled for a single pair-wise comparison
as recommended by the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011).We will exclude intervention arms
not appropriate for this review.
Dealing with missing data
We will contact investigators or study sponsors to obtain missing
datawhere possible (e.g. when a study is identified as abstract only).
Where this is not possible, and the missing data are considered
a potential source of serious bias, we will conduct a sensitivity
analysis to explore the impact of including such studies in the
overall assessment of results.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity across the
trials for the analysis of each outcome. Where we identify there to
be moderate to substantial heterogeneity (an I2 statistic between
30% and 100%), we will report it and examine possible causes
according to our prespecified subgroup analyses.
Assessment of reporting biases
If the results from more the 10 trials can be pooled, we will use a
funnel plot to explore possible small-study biases for the primary
outcomes.
Data synthesis
Wewill carry out meta-analyses only if it consideredmeaningful to
do so (i.e. if the interventions, participants and outcome measures
are similar enough for pooling to make sense). In the absence of
heterogeneity, we will use fixed-effect models. In the presence of
heterogeneity (an I2 statistic in excess of 30%), we will provide a
narrative overview without pooling data for analysis.
’Summary of findings’ table
Two review authors (MP and SB) will use the five GRADE con-
siderations (study limitations, consistency of effect, imprecision,
indirectness and publication bias) to assess the quality of a body
of evidence as it relates to the studies that contribute data to the
meta-analyses for the following outcomes: objective measures of
adherence to treatment, combined CVD event (fatal and non-fatal
events), adverse events and cognitive outcomes. We will use meth-
ods and recommendations described in Section 8.5 and Chapter
12 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011) using GRADEpro software. We will justify
all decisions to downgrade the quality of studies using footnotes
and we will make comments to aid readers’ understanding of the
review where necessary.
Subgroup analysis and investigation of heterogeneity
If there are sufficient studies, we will carry out the following sub-
group analyses for the primary outcome of adherence to treatment:
• income region (by World Bank income group) (World
Bank 2017);
• how text messages were developed (i.e. theory-based,
incorporating user views and based on evidence relating to
factors influencing behaviour-targeted versus other);
• intervention content (number behaviour change technique
employed coded according to the taxonomy developed by
Michie and colleagues (Michie 2015));
• delivery mechanisms (i.e. mobile phone messaging only,
mobile applications only, combined mobile phone messaging
and application, combined application and other).
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
• Only including studies with low risk of bias.
Reaching conclusions
We will base our conclusions only on findings from the quantita-
tive or narrative synthesis of included studies for this review. We
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will avoid making recommendations for practice and our impli-
cations for research will suggest priorities for future research and
outline what the remaining uncertainties are in the area.
A C K N OW L E D G E M E N T S
The review authors would like to acknowledge assistance provided
by staff of the Cochrane Heart Group and the template protocol
they made available.
R E F E R E N C E S
Additional references
Adler 2015
Adler AJ, Martin N, Mariani J, Tajer CD, Serrano NC,
Casas JP, et al. Mobile phone text messaging to improve
adherence to cardiovascular disease secondary prevention
interventions. Cochrane Database of Systematic Reviews
2015, Issue 8. [DOI: 10.1002/14651858.CD011851]
Anglada-Martinez 2015
Anglada-Martinez H, Riu-Viladoms G, Martin-Conde M,
Rovira-Illamola M, Sotoca-Momblona JM, Codina-Jane C.
Does mHealth increase adherence to medication? Results of
a systematic review. International Journal of Clinical Practice
2015;69(1):9–32.
Bobrow 2014
Bobrow K, Brennan T, Springer D, Levitt NS, Rayner B,
Namane M, et al. Efficacy of a text messaging (SMS) based
intervention for adults with hypertension: protocol for
the StAR (SMS Text-message Adherence suppoRt trial)
randomised controlled trial. BMC Public Health 2014;14:
28. [DOI: 10.1186/1471-2458-14-28]
Caird 2014
Caird JK, Johnston KA, Willness CR, Asbridge M, Steel P.
A meta-analysis of the effects of texting on driving. Accident
Analysis & Prevention 2014;71:311–8.
Chowdhury 2013
Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi
S, Moore C, et al. Adherence to cardiovascular therapy:
a meta-analysis of prevalence and clinical consequences.
European Heart Journal 2013;34(38):2940–8.
Douglas 2013
Douglas N, Free C. ’Someone batting in my corner’:
experiences of smoking-cessation support via text message.
British Journal of General Practice 2013;63(616):e768–76.
Free 2016
Free C, McCarthy O, French RS, Wellings K, Michie
S, Roberts I, et al. Can text messages increase safer sex
behaviours in young people? Intervention development
and pilot randomised controlled trial. Health Technology
Assessment (Winchester, England) 2016;20(57):1–82.
Higgins 2011
Higgins JP, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
ICT 2016
ICT. Key ICT indicators for developed and developing
countries and the world, 2016. www.itu.int/en/ITU-D/
Statistics/Pages/facts/default.aspx (accessed 6 October
2016).
Lavikainen 2016
Lavikainen P, Helin-Salmivaara A, Eerola M, Fang G,
Hartikainen J, Huupponen R, et al. Statin adherence and
risk of acute cardiovascular events among women: a cohort
study accounting for time dependent confounding affected
by previous adherence. BMJ Open 2016;6(6):e011306.
[DOI: 10.1136/bmjopen-2016-011306]
Lefebvre 2011
Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching
for studies. In: Higgins JP, Green S, editor(s). Cochrane
Handbook for Systematic Reviews of Interventions Version
5.1.0 (updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Michie 2015
Michie S, Wood CE, Johnston M, Abraham C, Francis
JJ, Hardeman W. Behaviour change techniques: the
development and evaluation of a taxonomic method for
reporting and describing behaviour change interventions
(a suite of five studies involving consensus methods,
randomised controlled trials and analysis of qualitative
data). Health Technology Assessment 2015;19(99):1–187.
Naderi 2012
Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that
prevent cardiovascular disease: meta-analysis on 376,162
patients. American Journal of Medicine 2012;125(9):882–7.
Park 2014a
Park LG, Howie-Esquivel J, Chung ML, Dracup K. A text
messaging intervention to promote medication adherence
for patients with coronary heart disease: a randomized
6Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular
disease in adults (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
controlled trial. Patient Education and Counselling 2014;94
(2):261–8.
Park 2014b
Park LG, Howie-Esquivel J, Dracup K. A quantitative
systematic review of the efficacy of mobile phone
interventions to improve medication adherence. Journal of
Advanced Nursing 2014;70(9):1932–53.
Piepoli 2016
Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons
C, Catapano AL, et al. 2016 European Guidelines on
cardiovascular disease prevention in clinical practice The
Sixth Joint Task Force of the European Society of Cardiology
and Other Societies on Cardiovascular Disease Prevention
in Clinical Practice (constituted by representatives of 10
societies and by invited experts) developed with the special
contribution of the European Association for Cardiovascular
Prevention & Rehabilitation (EACPR). European Journal of
Preventive Cardiology 2016;23(11):NP1–NP96.
Piette 2012
Piette JD, Datwani H, Gaudioso S, Foster SM, Westphal
J, Perry W, et al. Hypertension management using mobile
technology and home blood pressure monitoring: results
of a randomized trial in two low/middle-income countries.
Telemedicine and e-Health 2012;18(8):613–20.
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Smith 2015
Smith C, Ngo TD, Gold J, Edwards P, Vannak U, Sokhey
L, et al. Effect of a mobile phone-based intervention on
post-abortion contraception: a randomized controlled trial
in Cambodia. Bulletin of the World Health Organization
2015;93(12):842–50A.
USPSTF 2014
U.S. Preventive Services Task Force. The guide
to clinical preventive services: recommendations
of the U.S. Preventive Services Task Force, 2014.
www.uspreventiveservicestaskforce.org/Page/Name/tools-
and-resources-for-better-preventive-care (accessed 11 April
2017).
Vinogradova 2016
Vinogradova Y, Coupland C, Brindle P, Hippisley-Cox
J. Discontinuation and restarting in patients on statin
treatment: prospective open cohort study using a primary
care database. BMJ 2016;353:i3305. [DOI: https://
doi.org/10.1136/bmj.i3305]
WHO 2003
World Health Organization. Adherence to long-term
therapies: evidence for action, 2003. www.who.int/chp/
knowledge/publications/adherence_report/en/ (accessed 15
February 2017).
WHO 2007
World Health Organization. Prevention of cardiovascular
disease: guidelines for assessment and management of
cardiovascular risk, 2007. www.who.int/cardiovascular_
diseases/publications/Prevention_of_Cardiovascular_
Disease/en/ (accessed 15 February 2017).
WHO 2011
World Health Organization. Global Atlas on Cardiovascular
Disease Prevention and Control, 2011. www.who.int/
cardiovascular_diseases/publications/atlas_cvd/en/ (accessed
15 February 2017).
WHO 2016
World Health Organization. Cardiovascular diseases
(CVDs) Fact Sheet N°317, 2016. www.who.int/
mediacentre/factsheets/fs317/en/ (accessed 24 May 2017).
World Bank 2017
World Bank. World Development Indicators 2017.
Washington, DC: World Bank. License: Creative
Commons Attribution CC BY 3.0 IGO. https://
openknowledge.worldbank.org/handle/10986/26447
(accessed 30 May 2017) 2017.
∗ Indicates the major publication for the study
7Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular
disease in adults (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Preliminary MEDLINE (Ovid) search strategy
1 exp Cell Phones/
2 ((cell* or mobile) adj (phone* or telephon*)).tw.
3 (cellphone* or mobiles or smartphone*).tw.
4 ((mobile or handheld or hand-held or cell* or phone*) adj2 (device* or technolog* or app* or health*)).tw.
5 Text Messaging/
6 sms.tw.
7 ((text or short or multimedia or multi-media or mms) adj1 messag*).tw.
8 (texting* or texted or texter*).tw.
9 Telemedicine/
10 (mhealth or m-health or ehealth or e-health or telemedicine* or telehealth or telemonitor*).tw.
11 Reminder Systems/
12 (reminder* adj (text* or system* or messag*)).tw.
13 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14 exp Cardiovascular Diseases/
15 cardio*.tw.
16 cardia*.tw.
17 heart*.tw.
18 coronary*.tw.
19 angina*.tw.
20 ventric*.tw.
21 myocard*.tw.
22 pericard*.tw.
23 isch?em*.tw.
24 emboli*.tw.
25 arrhythmi*.tw.
26 thrombo*.tw.
27 atrial fibrillat*.tw.
28 tachycardi*.tw.
29 endocardi*.tw.
30 (sick adj sinus).tw.
31 hypertensi*.tw.
32 exp Hyperlipidemias/
33 hyperlipid*.tw.
34 hyperlip?emia*.tw.
35 hypercholesterol*.tw.
36 hypercholester?emia*.tw.
37 hyperlipoprotein?emia*.tw.
38 hypertriglycerid?emia*.tw.
39 arteriosclerosis.tw.
40 atherosclerosis.tw.
41 exp Cholesterol/
42 cholesterol.tw.
43 Blood Pressure/
44 ((high* or raise* or elevat* or heighten* or increas*) adj3 (blood adj2 pressure)).tw.
45 ((high* or raise* or elevat* or heighten* or increas*) adj3 (BP or DBP or SBP)).tw.
46 ((diastolic or systolic or pulse) adj pressure).tw.
47 exp Stroke/
48 (stroke or strokes).tw.
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49 cerebrovasc*.tw.
50 cerebral vascular.tw.
51 apoplexy.tw.
52 ((brain* or cerebral or lacunar) adj2 infarct*).tw.
53 peripheral arter* disease*.tw.
54 aortic*.tw.
55 (arterial adj occlus*).tw.
56 infarct*.tw.
57 multiple risk factor.tw.
58 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or
36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57
59 randomized controlled trial.pt.
60 controlled clinical trial.pt.
61 randomized.ab.
62 placebo.ab.
63 clinical trials as topic.sh.
64 randomly.ab.
65 trial.ti.
66 59 or 60 or 61 or 62 or 63 or 64 or 65
67 exp animals/ not humans.sh.
68 66 not 67
69 13 and 58 and 68
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